A Double-Blind, Placebo-Controlled Study With Open-Label Follow-Up To Determine the Safety and Efficacy of r-HuEPO in AIDS Patients With Anemia Induced by Their Disease and AZT Therapy
Not Applicable
Completed
- Conditions
- HIV InfectionsCytopenias
- Registration Number
- NCT00002072
- Lead Sponsor
- Ortho Pharmaceuticals
- Brief Summary
To determine the safety and efficacy of erythropoietin (r-HUEPO) administered to AIDS patients with anemia secondary to their disease and/or concomitant zidovudine (AZT) therapy.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie r-HuEPO's efficacy in treating anemia in HIV-infected patients on AZT?
How does r-HuEPO compare to standard-of-care anemia treatments in AIDS patients with AZT-induced cytopenias?
Which biomarkers correlate with response to r-HuEPO in HIV-related anemia and AZT-induced anemia?
What are the known adverse events associated with r-HuEPO in immunocompromised HIV patients and how are they managed?
Are there combination therapies involving r-HuEPO that improve outcomes for AIDS-related anemia compared to monotherapy?
Trial Locations
- Locations (1)
Ortho Pharmaceutical Corp
🇺🇸Raritan, New Jersey, United States
Ortho Pharmaceutical Corp🇺🇸Raritan, New Jersey, United States